CBS 2019
CBSMD教育中心
中 文

推荐文献

Abstract

Recommended Article

Inflammation: A New Target For CAD Treatment and Prevention Blood CSF1 and CXCL12 as Causal Mediators of Coronary Artery Disease Use of Risk Assessment Tools to Guide Decision-Making in the Primary Prevention of Atherosclerotic Cardiovascular Disease A Special Report From the American Heart Association and American College of Cardiology Temporal trends in percutaneous coronary interventions thru the drug eluting stent era: Insights from 18,641 procedures performed over 12-year period Predicting the 10-Year Risks of Atherosclerotic Cardiovascular Disease in Chinese Population: The China-PAR Project (Prediction for ASCVD Risk in China) ACC临床简报:新型冠状病毒对心脏的影响(2019-nCoV) Incidence, Treatment, and Outcomes of Coronary Perforation During Chronic Total Occlusion Percutaneous Coronary Intervention Correction of a pathogenic gene mutation in human embryos

Review Article2017 Feb 7;69(5):556-569.

JOURNAL:J Am Coll Cardiol. Article Link

Mode of Death in Heart Failure With Preserved Ejection Fraction

Vaduganathan M, Patel RB, Butler J et al. Keywords: epidemiology; mortality; outcomes

ABSTRACT

Little is known about specific modes of death in patients with heart failure with preserved ejection fraction(HFpEF). Herein, the authors critically appraise the current state of data and offer potential future directions. They conducted a systematic review of 1,608 published HFpEF papers from January 1, 1985, to December 31, 2015, which yielded 8 randomized clinical trials and 24 epidemiological studies with mode-of-death data. Noncardiovascular modes of death represent an important competing risk in HFpEF. Although sudden death accounted for ∼25% to 30% of deaths in trials, its definition is nonspecific; it is unclear what proportion represents arrhythmic deaths. Moving forward, reporting and definitions of modes of death must be standardized and tailored to the HFpEF population. Broad-scale systematic autopsies and long-term rhythm monitoring may clarify the underlying pathology and mechanisms driving mortal events. There is an unmet need for a longitudinal multicenter, global registry of patients with HFpEF to map its natural history.